New Products
| Cat.No. | Product Name | Information | Added |
|---|---|---|---|
| E6695 | 3α-Aminocholestane | May 08 2026 | |
| E6516 | L-Glutamine-13C5 | May 08 2026 | |
| E6462 | IAMA-6 | IAMA‑6 (ARN23746) is a potent, selective, and orally bioavailable inhibitor of the NKCC1 cotransporter. It exhibits the potential to be primarily used in research to treat cognitive impairment in Down syndrome and autism by regulating intracellular chloride homeostasis. | May 07 2026 |
| E6718 | Polfurmetinib | May 06 2026 | |
| E6737 | flizasertib | May 06 2026 | |
| E6733 | Adrixetinib TFA | May 06 2026 | |
| E6732 | Mesutoclax | May 05 2026 | |
| E5965 | BMS-986458 | May 05 2026 | |
| E6729 | RGH-857 | May 05 2026 | |
| E6713 | BLU-808(SAR449028) | BLU-808 (SAR449028) is a potent and selective inhibitor of wild‑type c‑KIT and potently inhibits c‑KIT–dependent phosphorylation and proliferation. It also exhibits therapeutic benefit to patients suffering from wild‑type c‑KIT–mediated mast cell disorders. | Apr 28 2026 |
| E6569 | MD-4251 | MD-4251 is an orally active PROTAC degrader of MDM2. It potently degrades MDM2 in RS4;11 cells with a DC50 of 0.2 nM and activates p53. | Apr 28 2026 |
| E0865 | DFHBI-1T | DFHBI‑1T is a membrane‑permeable, non‑toxic fluorogenic probe that acts as a ‘light‑up’ sensor for RNA imaging in live cells. It specifically binds to RNA aptamers such as Broccoli, Spinach, and Spinach2, yielding strong green fluorescence with high signal‑to‑noise ratios. | Apr 28 2026 |
| E6494 | ATR-258 | ATR-258 (Compound 15) is a specific agonist of GRK-biased β2-adrenergic receptor (β2AR) with a pEC50 of 6.87 that increases glucose uptake with low cAMP generation. | Apr 27 2026 |
| E6773 | Olorofim(F901318) | Olorofim (F901318) is a reversible inhibitor of dihydroorotate dehydrogenase (DHODH), an oxidoreductase that catalyses the fourth step in the de novo synthesis of pyrimidines. It exhibits potential for the treatment of invasive mould infections and thermally dimorphic fungi that are refractory to or resistant to clinically available antifungals. | Apr 26 2026 |
| E6776 | AP-503 | AP-503 is a selective agonist of GPR133/ADGRD1 with an EC50 of 1.21 nM. It exhibits the potential to be used in research on the prevention of muscle-related diseases and vestibular dysfunction. | Apr 26 2026 |
| E6582 | LysoTracker Red(LysoTracker Red DND-99) | LysoTracker Red (LysoTracker Red DND-99) is an acidotropic, red-fluorescent probe (Ex/Em 577/590 nm) that selectively stains lysosomes and late endosomes in live cells. As a hydrophobic weak base, it freely diffuses across membranes at neutral pH (~7.4), becomes protonated in acidic compartments (pH 4.5-6.0), and traps via charge retention, preventing efflux for high-contrast imaging. | Apr 23 2026 |
| E5849 | KT-253 | KT-253 (Seldegamadlin) is a potent, selective heterobifunctional MDM2 degrader with a DC50 of 0.4 nM and p53 stabilizer. It also exhibits antitumor activity across p53 wild-type haematologic and solid tumours. | Apr 23 2026 |
| E6528 | BBT-176 | BBT-176 is a first-in-class reversible fourth-generation EGFR TKI with potent activity against osimertinib-resistant mutations with an IC50 of 49 nM (Del19/T790M/C797S), 202 nM (L858R/T790M/C797S), 42 nM (Del19/C797S), and 183 nM (L858R/C797S) in Ba/F3 cells. | Apr 21 2026 |
| E6738 | BCFTP | BCFTP is a potent, orally active, selective positive allosteric modulator (PAM) of human MrgprX1 that enhances endogenous ligand signalling to inhibit spinal C-fibre nociceptive transmission, thereby relieving heat hyperalgesia and spontaneous pain in neuropathic models without itch or tolerance. | Apr 21 2026 |
| E6663 | DDO-02267 | DDO‑02267 is a selective, lysine‑targeting covalent inhibitor of ALKBH5, with an IC50 of 0.49 μM. DDO‑02267 increases m⁶A levels and targets the ALKBH5–AXL signalling axis in AML cells. It exhibits the potential to serve as a chemical probe for investigating the biological function of the mRNA demethylase ALKBH5. | Apr 21 2026 |
| A2179 | Anti-Mouse CD41-Invivo | Anti-Mouse CD41-Invivo specifically binds to CD41, which is also known as glycoprotein IIb (gpIIb, GP IIb), Integrin α IIb chain, or Integrin alpha 2b. CD41 is a transmembrane glycoprotein that is encoded by Itga2b. CD41 associates with Integrin β3 chain (gpIIIa or CD61) to form the gpIIb/IIIa (CD41/CD61) complex. | Apr 20 2026 |
| E1270 | Afimetoran( BMS-986256) | Afimetoran (BMS-986256) is an orally active and selective antagonist of TLR7/8 that potently inhibits NF-κB activation and reverses TLR7-mediated steroid resistance in pDCs. | Apr 19 2026 |
| E0874 | Ulotaront hydrochloride | Ulotaront hydrochloride (SEP-363856 hydrochloride) is an orally active, CNS-penetrant psychotropic agent that acts as an agonist of the trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A receptor. It acts as an antipsychotic and used for the treatment of schizophrenia. | Apr 19 2026 |
| E0873 | Niacin hydrochloride | Niacin hydrochloride (Nicotinic acid; Vitamin B3) is a direct and noncompetitive inhibitor of hepatocyte diacylglycerol acyltransferase–2(DGAT2), a key enzyme for TG synthesis, which results in accelerated intracellular hepatic apo B degradation and the decreased secretion of VLDL and LDL particles. | Apr 19 2026 |
| E6631 | Oxamic acid | Oxamic acid (Oxamate) is a classical inhibitor of lactate dehydrogenase-A (LDH-A) that competitively blocks the conversion of pyruvate to lactate. It also induces G2/M arrest and apoptosis, and increases radiosensitivity in nasopharyngeal carcinoma cells. | Apr 16 2026 |
| E6711 | ACI-19626 | ACI‑19626 (TDP‑43‑IN‑2) is a first‑in‑class, small‑molecule PET tracer that specifically binds to pathological TDP‑43 aggregates, which are key drivers of neurodegeneration in diseases such as ALS, FTD, and LATE. | Apr 16 2026 |
| F7735 | SirT4 Antibody [C24N9] | Apr 15 2026 | |
| F2359 | Phospho-GSK3β (Y216)/GSK3α (Y279) Antibody [F22P22] | Apr 15 2026 | |
| F8456 | ORC2 Antibody [P19N22] | Apr 15 2026 | |
| E6682 | CT-996(RO7795081，RG6652） | CT-996 (RO7795081, RG6652) is an orally active, cAMP-biased agonist of GLP-1R with an EC50 ≈ 0.049 nM for cAMP, with minimal β-arrestin recruitment and receptor internalisation, suitable for research on type 2 diabetes and obesity. | Apr 14 2026 |
| E0863 | Talfirastide acetate | Talfirastide acetate (TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate) is an endogenous heptapeptide of the renin–angiotensin system (RAS) with a cardioprotective role due to its anti‑inflammatory and anti‑fibrotic activities in cardiac cells. It inhibits purified canine ACE activity with an IC50 of 0.65 μM and also acts as a local synergistic modulator of kinin‑induced vasodilation by inhibiting ACE and promoting nitric oxide release. | Apr 14 2026 |
| E6787 | Rineterkib hydrochloride | Rineterkib hydrochloride is an orally active, potent inhibitor of RAF and ERK1/2, exhibiting preclinical activity in multiple MAPK-activated cancer cell lines and xenograft models. | Apr 14 2026 |
| E6679 | PhIP | PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) is a carcinogenic heterocyclic aromatic amine often generated in thermal processing of food. It induces DNA Damage via CYP1A2 activation to hydroxylated metabolites forming C8-dG adducts and mutations. It also binds ERα to drive estrogenic signalling independent of genotoxicity, promoting epigenetic changes in MCF-7 breast cells akin to 17-β-estradiol, contributing to tissue-specific carcinogenesis in breast, colon, and prostate. | Apr 13 2026 |
| E0866 | Glycerophosphoric acid | Glycerophosphoric acid is a naturally occurring compound and an a‑site substrate analogue that, when bound to the a‑site, strongly inhibits the reaction of indole and nucleophilic indole analogues with E(A‑A). It also serves as a structural precursor of glycerophospholipids in cell membranes, contributing to membrane organization, fluidity, and transport regulation. | Apr 12 2026 |
| F4153 | Phospho-Jak2 (Tyr1007/1008) Antibody [L12G1] | Apr 09 2026 | |
| F4999 | METTL14 Antibody [A8N22] | Apr 09 2026 | |
| E6546 | PF-07899895 | PF-07899895 (Compound 34) is an inhibitor of SIK, with an IC50 of 1.2 nM, 0.9 nM, and 1.8 nM for SIK1, SIK2, and SIK3, respectively. It also modulates the anti-inflammatory cytokine IL-10 in immune cells and exhibits potential applicable research related to inflammatory diseases. | Apr 08 2026 |
| E6742 | Z218484536 | Z218484536 is a selective and brain-penetrant inhibitor of phosphoserine phosphatase (PSPH) that binds to PSPH with a Kd of approximately 0.23 μM. | Apr 08 2026 |
| E0858 | Lavofloxacin lactate | Lavofloxacin lactate, the lactate salt of levofloxacin, is a fluoroquinolone antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria. It inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair, leading to double-strand DNA breaks and bacterial cell death. | Apr 08 2026 |
| E1034 | PKH26 | PKH26 is a red fluorescent lipophilic dye (Ex/Em = 551/567 nm) that stably integrates into the lipid bilayer of cell membranes via its long aliphatic hydrocarbon tails, enabling long-term tracking without significant cytotoxicity or transfer between cells. | Apr 08 2026 |
| E6660 | FMC-376 | FMC-376 is a selective and irreversible dual inhibitor of both the ON and OFF states of KRASG12C. It binds covalently to the mutant cysteine at position 12 in KRAS G12C and directly blocks both the ON and OFF conformations of the mutant KRAS protein, leading to a complete and durable blockade of downstream signalling. FMC-376 exhibits robust anti-tumour activity in vivo. | Apr 08 2026 |
| E5864 | EG01377 Dihydrochloride | EG01377 dihydrochloride is a potent, bioavailable, and selective inhibitor of neuropilin‑1 (NRP1), with a Kd of 1.32 μM and IC50 609 nM for both NRP1‑a1 and NRP1‑b1. It also exhibits antiangiogenic, antimigratory, and antitumor effects in vitro. | Apr 08 2026 |
| E1577 | AZD4747 | AZD4747 is a selective, blood‑brain barrier‑permeable inhibitor of mutant GTPase KRASG12C, with the potential to treat KRASG12C‑positive tumours, including central nervous system (CNS) metastases. | Apr 08 2026 |
| S7151 | Garcinol | Garcinol is a polyisoprenylated benzophenone compound isolated from the fruit rind of Garcinia indica. It acts as a potent natural inhibitor of Histone Acetyltransferase (HATs), including p300 and PCAF, with IC50 of ~7 μM and 5 μM, respectively. It also exhibits anti-cholinesterase activity against AChE and BChE with an IC50 of 0.66 μM and 7.39 μM, respectively. | Apr 08 2026 |
| E6681 | Tinlarebant | Tinlarebant (LBS-008; BPN-14967) is an oral, non-retinoid antagonist of RBP4, which exhibits potential to treat Stargardt disease and advanced dry age-related macular degeneration. | Apr 08 2026 |
| P1254 | Rusfertide(PTG-300) | Rusfertide (PTG-300) is a hepcidin mimetic that targets ferroportin, inducing its internalisation and degradation to block cellular iron export into the blood. By limiting transferrin saturation (TSAT), it reduces systemic labile iron toxicity and prevents organ iron deposition. Rusfertide exhibits the potential treatment for Hereditary Hemochromatosis and haemoglobinopathies like beta-thalassaemia and also helps to improve anaemia by promoting more effective erythropoiesis. | Apr 06 2026 |
| E6700 | G-6599 | G-6599 is a potent monovalent degrader of SMARCA2/SMARCA4 that covalently binds a cysteine on E3 ligase FBXO22, forming a ternary complex for ubiquitin-proteasome degradation. It exhibits potential research applications in androgen-dependent prostate cancer and SMARCA4-mutant non-small cell lung cancer. | Apr 06 2026 |
| E6476 | SBI-810 hydrochloride | SBI‑810 hydrochloride is a β‑arrestin–biased, functionally selective allosteric modulator of neurotensin receptor 1 (NTSR1) that alters NTSR1‑mediated G protein signalling in a G protein–specific manner when the endogenous ligand neurotensin (NT) is present, fully antagonising NT‑induced Gq activation, partially antagonising Gi1 activation, and remaining permissive toward NTSR1‑mediated activation of GoA and G12. | Mar 30 2026 |
| E5769 | MY-1B | MY‑1B is a covalent inhibitor of the RNA Methyltransferase NSUN2, with an IC50 of 1.3 μM. MY‑1B stereoselectively targets the active-site cysteine residue C271 of NSUN2 and can be used to probe the function of NSUN2 in RNA methylation-related processes. | Mar 29 2026 |
| E6727 | GDC-4198 | Mar 26 2026 | |
| S9814 | BMS-986202 | BMS-986202 is a potent, selective and orally active inhibitor of TYK2 that binds to the TYK2 pseudokinase domain (JH2) with an IC50 of 0.19 nM and a Ki of 0.02 nM. | Mar 24 2026 |
| E1584 | CCR6 inhibitor 1 | CCR6 inhibitor-1 is a potent and selective inhibitor of CCR6 with IC50 of 0.45 nM and 6 nM for monkey and human CCR6, respectively. It potently inhibits human B-cell migration and ERK phosphorylation, exhibiting potential as a treatment for autoimmune diseases. | Mar 24 2026 |
| E4769 | Aleniglipron (GSBR-1290) | Aleniglipron (GSBR-1290) is a potent, orally available agonist of GLP-1R that selectively activates the Gαs–cAMP signalling pathway without detectable β‑arrestin recruitment. | Mar 24 2026 |
| E1097 | Famitinib (SHR1020) | Famitinib (SHR1020), an orally active inhibitor of multi-targeted kinase, which inhibits the activity of c‑Kit, VEGFR‑2, and PDGFRβ with IC50 of 2.3 nM, 4.7 nM, and 6.6 nM, respectively. | Mar 23 2026 |
| E6693 | PKUMDL-WQ-2101 | PKUMDLWQ2101 is a nonNAD⁺competing allosteric inhibitor of phosphoglycerate dehydrogenase (PHGDH) with an IC50 of 34.8 μM. It exhibits antitumor activity, selectively inhibits de novo serine synthesis in cancer cells, and reduces tumor growth in vivo. | Mar 23 2026 |
| P1273 | Ecnoglutide（XW003） | Ecnoglutide (XW003) is a long-acting, cAMP-biased agonist of the GLP-1 Receptor that selectively enhances cAMP signalling over β-arrestin recruitment, and exhibits potential for the treatment of type 2 diabetes and obesity. | Mar 23 2026 |
| E6703 | MLT-985 | MLT-985 is a selective allosteric and orally active inhibitor of MALT1 with an IC50 of 3 nM. It inhibits MALT1-dependent signalling in ABC-DLBCL models and reduces cell growth and aberrant CARD11/BCL10/MALT1-complex activity in vitro. | Mar 23 2026 |
| E1475 | CFT1946 (Tagarafdeg) | CFT1946 (Tagarafdeg) is an orally bioavailable, CRBN‑based bifunctional degradation‑activating compound (BiDAC) that selectively targets mutant BRAFV600E for ubiquitin–proteasome–mediated degradation, with a DC50 of 14 nM in A375 melanoma cells. | Mar 23 2026 |
| E6751 | Sodium iodoacetate(Iodoacetic acid sodium salt) | Sodium iodoacetate(Iodoacetic acid sodium salt) is a specific, covalent inhibitor of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) that blocks glycolytic flux by alkylating the catalytic cysteine residue in the active site, thereby exerting glycolysis-inhibitory activity in cells and tissues. It also induces osteoarthritis-like joint degeneration and related pain models in experimental animals. | Mar 19 2026 |
| E6756 | MOCAc-PLGL(Dpa)AR | MOCAc-PLGL(Dpa)AR (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂) is a FRET-based fluorescent peptide substrate for MMPs including MMP-7 (matrilysin), MMP-2, and MMP-9, where the MOCAc fluorophore is quenched by Dpa until cleavage at the Gly-Leu bond produces >10-fold fluorescence increase for activity assays. | Mar 19 2026 |
| E6456 | PF-07248144(Prifetrastat) | PF-07248144 (Prifetrastat) is a potent and selective catalytic inhibitor of KAT6A and KAT6B that exhibits durable antitumor activity and the potential to treat metastatic breast cancer. | Mar 16 2026 |
| F0806 | Phospho-VEGF Receptor 2 (Tyr1059) Antibody [J6L3] | Mar 12 2026 | |
| F3541 | Phospho-Akt (Thr308) Antibody [F21G22] | AKT (phospho T308),AKT1 (phospho T308),pan-AKT (phospho T308),Phospho-Akt (Thr308) | Mar 12 2026 |
| F0653 | Phospho-VEGF Receptor 2 (Tyr951) Antibody [F15G14] | Phospho-VEGF Receptor 2 (Tyr951),VEGF Receptor 2 (phospho Y951) | Mar 12 2026 |
| F2677 | β Actin Antibody [H22G2] | ACTB,beta Actin,beta Actin Loading Control,beta-Actin,β-Actin | Mar 12 2026 |
| F4004 | ATF1 Antibody [H17A19] | Mar 12 2026 | |
| F3361 | 6X His tag Antibody [G4E22] | 6X His tag,6XHIS,6x-His Tag,His-Tag,polyHistidine | Mar 12 2026 |
| E5879 | Elinzanetant | Elinzanetant (NT-814; BAY3427080) is a nonhormonal dual antagonist of NK1/NK3 receptor that reduces GnRH pulsatility by blocking neurokinin B (NK3) and substance P (NK1) effects on the reproductive axis in KNDy neurons. | Mar 12 2026 |
| E1593 | Camlipixant | Camlipixant (BLU-5937) is a potent, selective, non-competitive antagonist that targets the P2X3 homotrimeric receptor, with an IC50 of 25 nM for the hP2X3 homotrimeric form. | Mar 12 2026 |
| E6702 | Opitor-0 | Opitor-0 is a potent and selective inhibitor of mitochondrial dynamin-related protein Optic Atrophy 1 (OPA1) guanosine triphosphatase (GTPase), that regulates cristae remodelling and cytochrome c release, with an IC50 of 3 μM. | Mar 10 2026 |
| E8328 | Ro24-7429 | Ro24-7429 is a benzodiazepine derivative that acts as a potent, orally active antagonist of HIV-1's Tat transactivator protein, disrupting viral replication by inhibiting Tat-mediated transactivation of the HIV-1 long terminal repeat (LTR) promoter. It also inhibits RUNX1 (runt-related transcription factor 1), contributing to antifibrotic effects by reducing fibrosis markers in models like bleomycin-induced pulmonary fibrosis, alongside anti-inflammatory properties. | Mar 10 2026 |
| P1259 | Cagrilintide | Cagrilintide is a long-acting acylated amylin analogue functioning as a nonselective agonist at amylin receptors (AMYR) and calcitonin receptors (CTR). Its dual action promotes satiety, slows gastric emptying, and reduces food intake through brain-mediated pathways with the potential to treat obesity. | Mar 10 2026 |
| E4671 | ML334 | ML334 (LH601A) is a potent, cell-permeable activator of NRF2 that disrupts the Keap1-NRF2 protein-protein interaction by binding the Keap1 Kelch domain with a Kd of 1 μM, promoting NRF2 nuclear translocation and antioxidant gene expression. | Mar 08 2026 |
| E6698 | STL1267 | STL1267 is a potent agonist of REV-ERB, with Ki of 0.16 µM for REV-ERBα that crosses the blood-brain barrier, enhancing NCoR corepressor recruitment to repress circadian and metabolic genes. | Mar 08 2026 |
| E6697 | PACMA 31 | PACMA 31 is an irreversible, orally active inhibitor of protein disulfide isomerase (PDI) with an IC50 of 10 μM. It covalently binds PDI's active-site cysteines, inhibiting reductase/isomerase activity in a dose- and time-dependent manner per insulin aggregation assays. | Mar 01 2026 |
| E6661 | Ontunisertib | Ontunisertib (AGMB-129) is an oral, GI-restricted small molecule inhibitor of ALK5 (TGFβR1), exhibiting the potential to treat fibrostenosing Crohn’s disease (FSCD). It potently blocks pro-fibrotic TGFβ signalling locally in the GI tract via high first-pass metabolism. | Mar 01 2026 |
| E6659 | TYRA-200 | TYRA-200 is an orally bioavailable inhibitor of FGFR1/2/3 that exhibits potential to address clinically observed acquired resistance alterations in FGFR2, such as molecular brake and gatekeeper mutations. | Mar 01 2026 |
| F3556 | Phospho-FoxO1 (T24)/FoxO3a (T32) Antibody [M8K9] | Feb 28 2026 | |
| F0728 | FGFR3 Antibody [G21B24] | FGF Receptor 3,FGFR3,FGFR-3 | Feb 28 2026 |
| F1608 | Cleaved PARP1 Antibody [K10A21] | Feb 28 2026 | |
| F2463 | FADD Antibody [P17H10] | Feb 28 2026 | |
| F5322 | BRCC36 Antibody [M5D3] | Feb 28 2026 | |
| F7401 | SMARCD3/BAF60C Antibody [C13A4] | Feb 28 2026 | |
| F0346 | Phospho-PERK (Thr980) Antibody [E16F3] | Feb 28 2026 | |
| F3023 | IL-6 Antibody [F4K18] | IL-6 | Feb 28 2026 |
| F3061 | IL-1β Antibody [J24M1] | IL-1 beta,IL-1 beta (Pro-form),IL-1 beta/IL1B,IL-1 beta/IL-1F2,IL-1β | Feb 28 2026 |
| F2632 | BRCA1 Antibody [N12F20] | BRCA1 | Feb 28 2026 |
| F3067 | IL-1β Antibody [H12N7] | IL-1 beta,IL-1 beta (Pro-form),IL-1 beta/IL1B,IL-1 beta/IL-1F2,IL-1 | Feb 28 2026 |
| F3557 | Phospho-EGF Receptor (Tyr1045) Antibody [F16D14] | Feb 28 2026 | |
| F3443 | Phospho-p130 (Ser672) Antibody [E21C6] | Feb 28 2026 | |
| F4019 | SIRT7 Antibody [J3K9] | Feb 28 2026 | |
| F4814 | SOX10 Antibody [E22E2] | Feb 28 2026 | |
| F4857 | Apolipoprotein E Antibody [L10K14] | Feb 28 2026 | |
| F4146 | Phospho-Stat5 (Tyr694) Antibody [L6J15] | Feb 28 2026 | |
| F3968 | Phospho-EGFR (Tyr1101) Antibody [A24A1] | Feb 28 2026 | |
| E4770 | Jedi2 | Jedi2 is an activator of the Piezo1 channel that binds to mouse Piezo1 protein with a Kd of 2770 μM. | Feb 27 2026 |
| E6712 | PYCR1-IN-1 | PYCR1-IN-1 (compound 4) is an inhibitor of pyrroline-5-carboxylate reductase 1 (PYCR1) with an IC50 of 8.8 µM. It significantly reduces the levels of proline within a breast cancer cell line and exhibits anti-cell proliferation effect. | Feb 26 2026 |
| E6708 | HQ461 | HQ461 is a molecular glue degrader that promotes CDK12-DDB1-CUL4-RBX1 interaction, causing polyubiquitination and degradation of Cyclin K (CCNK). HQ461-mediated degradation of cyclin K impairs CDK12 function, resulting in decreased CDK12 substrate phosphorylation, downregulation of DNA damage response genes, and cell death. | Feb 26 2026 |
| E6637 | YCT529 | YCT-529 is a selective antagonist of retinoic acid receptor alpha (RARα) developed as a pyrrole-linked analog that potently inhibits RARα with an IC50 of 1.2 nM and greater than 300-fold selectivity over RARβ and RARγ. It also serves as oral non-hormonal male contraceptive effectively reduces sperm counts in mice and non-human primates by targeting the retinoid signaling pathway essential for spermatogenesis. | Feb 11 2026 |
| E6630 | NT-0527 | NT-0527 is a potent, specific, and brain-penetrant inhibitor of the NLRP3 inflammasome with oral bioavailability and demonstrated efficacy in an in vivo model of inflammation. | Feb 08 2026 |
| S8827 | Diprovocim | Diprovocim is a potent synthetic agonist that activates the human TLR1/TLR2 heterodimer with an EC50 of 110 pM in THP-1 cells. It also exhibits significant potential as an immune adjuvant. | Feb 04 2026 |
| E6670 | AC-4-130 | AC-4–130 is a potent, selective inhibitor of the STAT5 SH2 domain that directly binds to STAT5, blocking its phosphorylation, dimerization, and nuclear translocation. It acts by disrupting STAT5-dependent gene transcription, effectively reducing pathological STAT5 activity in acute myeloid leukaemia (AML). | Feb 03 2026 |
| E6675 | MC3482 | MC3482 is a specific, cell-permeable inhibitor of SIRT5 that mitigates microglia-induced neuroinflammation and neuronal apoptosis by regulating Annexin-A1 succinylation. It significantly improves long-term sensorimotor and cognitive function, exhibiting potential for anti-ischemic stroke treatment. | Feb 03 2026 |
| E6509 | AR420626 | AR420626 is a selective agonist of FFAR3 (GPR41) with an IC50 of 117 nM, that prevents serotonin-induced circular muscle relaxation ex vivo and defecation in vivo. | Feb 03 2026 |
| E6626 | STAT3-IN-3 | STAT3-IN-3 is a potent, selective chemical inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3) that has shown efficacy in mitigating drug resistance. | Feb 03 2026 |
| E8326 | HNHA | HNHA (N-hydroxy-7-(2-naphthylthio) heptanomide) is a cell-permeable inhibitor of histone deacetylase (HDAC) activity, a key enzyme in gene expression and carcinogenesis with an IC50 of 100 nM. It also exhibits anti-tumour activity both in vitro and in vivo. | Feb 03 2026 |
| E6726 | N-Hydroxysuccinimide | N-Hydroxysuccinimide (HOSu; 1-Hydroxy-2,5-pyrrolidinedione) is a crucial reagent that forms NHS esters via DCC-mediated carboxylic acid activation. These esters enable covalent protein/antibody coupling to surfaces through primary amine reactions. It also modifies microfluidic SPR sensors for bacterial pathogen detection. | Feb 01 2026 |
| A2177 | Anti-mouse IFNγR (CD119)-Invivo | Anti-mouse IFNγR (CD119)-Invivo reacts with the mouse IFNγR (interferon gamma receptor) α chain, also known as CD119 and IFNγ receptor 1. CD119 heterodimerizes with IFNγ receptor 2 (AF-1) to form the IFNγR, a Class II cytokine receptor. | Jan 26 2026 |
| A2178 | Anti-mouse/human IL-5-Invivo | Anti-mouse/human IL-5-Invivo reacts with mouse and human interleukin-5 (IL-5), a 26 kDa homodimeric cytokine. IL-5 stimulates B lymphocyte differentiation and proliferation and increases the secretion of IgM and IgA. | Jan 26 2026 |
| E1822 | Acoramidis hydrochloride | Acoramidis hydrochloride (AG10 hydrochloride) is an orally active, selective kinetic stabilizer of WT-transthyretin (TTR) and V122I mutant transthyretin (TTR), providing effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). | Jan 22 2026 |
| E6699 | Opiranserin hydrochloride | Opiranserin hydrochloride (VVZ-149 hydrochloride) is a non-opioid and non-NSAID analgesic that acts as a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50 of 0.86 μM and 1.3 μM, respectively. | Jan 22 2026 |
| S9883 | RMC-5552 | RMC-5552 is a selective bi-steric inhibitor of mTORC1, with the potential for treating mTORC1-activated tumours. It potently inhibits mTORC1-mediated phosphorylation of pS6K and p4EBP1 with IC50 values of 0.14 nM and 0.48 nM, respectively. | Jan 22 2026 |
| A2176 | Anti-mouse CD8α (53-6.7)-Invivo | Anti-mouse CD8α (53-6.7)-Invivo reacts with mouse CD8α. The CD8 antigen is a transmembrane glycoprotein that acts as a co-receptor for the T cell receptor (TCR). | Jan 20 2026 |
| E6671 | CMPD-39 | CMPD-39 (Compound 39) is a selective non-covalent inhibitor of USP30 with an IC50 of ~20 nM in in vitro enzyme assays. | Jan 19 2026 |
| E6515 | ML-60218 | ML-60218 is a broad-spectrum inhibitor of RNA polymerase III (pol III), with an IC50 of 32 μM for Saccharomyces cerevisiae and 27 μM for human pol III. ML-60218 disrupts pre-assembled viroplasms and impedes the formation of new ones, acting independently of de novo transcription of cellular RNAs. | Jan 19 2026 |
| F4016 | OGT Antibody [E11N9] | Jan 16 2026 | |
| F4050 | Phospho-AKT1 (Thr450) Antibody [H24E24] | Jan 16 2026 | |
| F4828 | FGF2 Antibody [E17H24] | Jan 16 2026 | |
| F2613 | Phospho-TAK1 (Ser439) Antibody [F17C11] | Jan 16 2026 | |
| F3409 | POLDIP2 Antibody [N1K14] | Jan 16 2026 | |
| F0402 | Phospho-TAK1 (Thr184/187) Antibody [G4C5] | Jan 16 2026 | |
| F5127 | CNBP Antibody [E10D2] | Jan 16 2026 | |
| F4827 | JAK3 Antibody [M5G12] | Jan 16 2026 | |
| F4751 | Phospho-MEK1 (Ser298) Antibody [L22P14] | Jan 16 2026 | |
| F4738 | FXR1 Antibody [G5P16] | Jan 16 2026 | |
| F4918 | Phospho-Akt1 (Ser129) Antibody [K23C4] | Jan 16 2026 | |
| P1262 | Eloralintide (LY-3841136) | Eloralintide (LY-3841136) is an AMYR agonist with potential applications in type 2 diabetes and obesity research. | Jan 14 2026 |
| E6411 | RP03707 | RP03707 is a PROTAC molecule designed to degrade KRASG12D, consisting of three components: a KRASG12D inhibitor (, red), a linker (black), and an E3 ligase ligand (blue). | Jan 14 2026 |
| E6653 | AR-C118925XX | AR-C118925XX is a P2Y2 receptor antagonist. It reduces ATP-induced IL-6 production and p38 phosphorylation. In mice, AR-C118925XX attenuates Bleomycin-induced dermal fibrosis. Additionally, it suppresses ATP-stimulated tumour growth. | Jan 14 2026 |
| E6651 | HGC652 | HGC652 is a TRIM21-dependent Molecular Glue degrader that binds the E3 Ubiquitin Ligase TRIM21 (Kd ≈ 0.06 µM) to induce a TRIM21–NUP98 ternary complex, driving the ubiquitination and selective degradation of nuclear pore complex proteins like NUP155, leading to nuclear pore collapse and cancer cell death. | Jan 14 2026 |
| P1269 | Pegcetacoplan acetate | Pegcetacoplan acetate, a PEGylated cyclic peptide, is the first approved inhibitor of complement component C3/C3b designed to treat adults with Paroxysmal Nocturnal Hemoglobinuria (PNH). It binds C3 and C3b to inhibit convertase-mediated C3 cleavage, blocking C3b opsonization (extravascular haemolysis) and downstream MAC formation (intravascular haemolysis). | Jan 13 2026 |
| E8319 | Ro 48-8071 fumarate | Ro 48-8071 fumarate is a potent, selective inhibitor of 2,3-oxidosqualene cyclase (OSC) (IC50 = 6.5 nM), a key enzyme downstream of HMG-CoA reductase that catalyses lanosterol formation in cholesterol biosynthesis. It reduces intracellular cholesterol levels without the feedback upregulation of HMG-CoA reductase seen with statins, providing a distinct, self-limiting regulatory loop for lowering LDL-C. Additionally, it also exhibits significant anti-cancer properties by inducing apoptosis and disrupting cell signalling in cancer models. | Jan 13 2026 |
| F4944 | SCG10/Stathmin-2 Antibody [D11B18] | Jan 12 2026 | |
| F4375 | Na+/H+ Exchanger-1 Antibody [K9D3] | Jan 12 2026 | |
| F4810 | PEN2 Antibody [E13J21] | Jan 12 2026 | |
| F3707 | Na(+)/K(+)-transporting ATPase (pan α subunit) Antibody [G11K19] | ATP1A1/ATP1A2/ATP1A3/ATP1A4 | Jan 12 2026 |
| F4620 | MMP-3 Antibody [K11K15] | Jan 12 2026 | |
| F2603 | Wnt3 and Wnt3a Antibody [J20B9] | Jan 12 2026 | |
| E6564 | VG-3927 | VG-3927 is a potent, selective, and brain-penetrant agonist of TREM2 that induces anti-inflammatory microglial activation and has the potential to treat Alzheimer's disease (AD). | Jan 12 2026 |
| F1719 | MBP tag Antibody [E2A2] | Maltose Binding Protein,MBP tag,MBP-probe | Jan 12 2026 |
| F2110 | Otoferlin Antibody [J18F12] | Jan 12 2026 | |
| E8330 | NIC3 | NIC3 is a selective inhibitor of nucleus accumbens-associated protein 1 (NAC1), a BTB/POZ domain-containing transcription corepressor overexpressed in cancers. It binds the conserved Leu-90 residue in NAC1's BTB domain, disrupting homodimerization essential for nuclear body formation and stability. | Jan 05 2026 |
| E8325 | Quadrol | Quadrol (N,N,N′,N′-Tetrakis(2-hydroxypropyl)ethylenediamine, EDTP) is an immunostimulant which is considered as a potentially useful active molecule for accelerating wound healing. Quadrol can form a complex with Ca²⁺, mediate the entry of Ca²⁺ into macrophages, and stimulate macrophage activation. | Jan 05 2026 |
| E8327 | DHBS | DHBS (Sodium 3,5-dichloro-2-hydroxybenzenesulphonate) is used in conjunction with 4-aminoantipyrine (4-AAP) and hydrogen peroxide (H2O2) for chromogenic quantitation of uric acid in serum and urine samples. | Jan 05 2026 |
| E6635 | MC3138 | MC3138 is a selective activator of SIRT5 and inhibits proliferation in SIRT5-low PDAC cell lines and organoids by restoring SIRT5-mediated desuccinylation and deacetylation. | Jan 04 2026 |
| E0853 | 360A | 360A stabilises G-quadruplex structures and inhibits telomerase activity, showing an IC50 of 300 nM in TRAP-G4 assays. | Dec 31 2025 |
| A2175 | Anti-mouse CD11c-Invivo | Anti-mouse CD11c-Invivo reacts with mouse CD11c, the most widely used defining marker for murine dendritic cells (DCs). CD11c is also known as integrin alpha-X (Itgax) and CD11 antigen-like family member C. | Dec 30 2025 |
| E6667 | JNJ-9350 | JNJ-9350 is a chemical probe that inhibits spermine oxidase (SMOX) with an IC50 of 0.01 μM. This compound also shows inhibitory activity against polyamine oxidase (PAO), exhibiting an IC50 of 0.79 μM. JNJ-9350 has potential applications in cancer research. | Dec 24 2025 |
| E8329 | VQW-765 | VQW-765 (AQW-051) is an orally active agonist targeting the alpha-7 nicotinic acetylcholine receptor (α7-nAChR), exhibiting a pKD of 7.56 for the human recombinant α7-nAChR. This compound demonstrates anxiolytic-like activity in animal models. VQW-765 has potential applications in anxiety disorder and acute performance anxiety studies. | Dec 24 2025 |
| E1789 | Asundexian | Asundexian (BAY 2433334) is an orally administered inhibitor of coagulation Factor XIa (FXIa). It binds reversibly to the FXIa active site with high affinity, blocking its enzymatic function. In buffer systems, Asundexian exhibits an IC50 of 1 nM against human FXIa. | Dec 24 2025 |
| E6656 | STAT3-IN-13 | STAT3-IN-13 (compound 6f) is a STAT3 inhibitor. It exhibits anti-proliferative activity and binds to the STAT3 SH2 domain with a KD of 0.46 μM. This compound inhibits STAT3 Y705 phosphorylation and downstream target gene expression. In vitro studies show STAT3-IN-13 induces apoptosis, while in vivo experiments demonstrate its ability to suppress tumour growth and metastasis. STAT3-IN-13 has potential applications in cancer research. | Dec 24 2025 |
| E5872 | BBO-10203 | BBO-10203 inhibits PI3Kα and KRASG12C by covalently binding to Cys242 in the PI3Kα RAS-Binding Domain. It inhibits both GTP-bound and GDP-bound KRASG12C states, with IC50 and EC50 values of 0.031 nM and 0.02 nM respectively. This compound interferes with RAS-PI3Kα interaction, suppressing RAS-dependent PI3Kα activation. It decreases pERK levels, inhibits cell proliferation, and causes G1 phase arrest and apoptosis. BBO-10203 has potential applications in breast cancer, colorectal cancer, and non-small cell lung cancer research. | Dec 24 2025 |
| E8324 | GE11 | GE11 is an active peptide that binds with colloidal drug delivery systems, serving as smart carriers for antitumor drugs in cancer research. | Dec 21 2025 |
| E0850 | DPhPC | DPhPC is a phosphatidylcholine (PC) derivative employed in the synthesis of bilayer vesicle phospholipids. The DPhPC bilayer membranes exhibit minimal ion leakage in the absence of pores or ion channels, making them suitable for investigating ion channel activity and membrane potential regulation. DPhPC-based nanoliposomes (NTG) enhance nitric oxide (NO) bioavailability and demonstrate anti-inflammatory properties. | Dec 14 2025 |
| F4429 | Uteroglobin/CC10 Antibody [H18P18] | Dec 12 2025 | |
| F4670 | Keratin 18 Antibody [M2J10] | Dec 12 2025 | |
| F4793 | IRF-9 Antibody [N16H20] | Dec 12 2025 | |
| F4438 | GPX1/2 Antibody [L20K22] | Dec 12 2025 | |
| F1291 | JAK3 Antibody [F8D8] | Dec 12 2025 | |
| F1643 | Glutathione Antibody [A11G7] | Dec 12 2025 | |
| F2030 | 5-hydroxymethylcytosine Antibody [B13H23] | Dec 12 2025 | |
| F2031 | VSV-G tag Antibody [N12B16] | VSV Glycoprotein,VSV-G tag | Dec 12 2025 |
| F2238 | Influenza A Virus M2 Protein Antibody [L21L24] | Influenza A M2, Influenza A Virus M2 Protein | Dec 12 2025 |
| F3018 | IFN-γ Antibody [A4P20] | IFN-γ,Interferon gamma | Dec 12 2025 |
| F3039 | Acetyl-CoA Carboxylase 2 Antibody [E20M20] | Dec 12 2025 | |
| F2353 | VEGFB Antibody [E11E24] | VEGFB, VEGF-B | Dec 12 2025 |
| F2701 | Thymine Dimer Antibody [E15K19] | Dec 12 2025 | |
| F2741 | uPA Antibody [F9E24] | uPA, Urokinase | Dec 12 2025 |
| F3241 | Phospho-β Catenin (Ser675) Antibody [D16B23] | Dec 12 2025 | |
| F3306 | Phospho-Nephrin (Tyr1217) Antibody [L5D2] | Dec 12 2025 | |
| F3647 | Phospho-EGFR (Tyr992) Antibody [F20E14] | EGFR (phospho Y992), Phospho-EGF Receptor (Tyr992) | Dec 12 2025 |
| F3783 | Phospho-JAK1 (Tyr1034 + Tyr1035) Antibody [F22D15] | JAK1 (phospho Y1034 + Y1035), Phospho-Jak1(Tyr1034/1035) | Dec 12 2025 |
| F4985 | Cleaved PARP (Asp214) Antibody [C3D4] | Dec 12 2025 | |
| F4192 | Caspase-1 Antibody [C2H20] | Dec 12 2025 | |
| F4203 | ATF-6 Antibody [G8H4] | Dec 12 2025 | |
| F4779 | Mannose Receptor Antibody [E13A19] | Dec 12 2025 | |
| F2860 | Phospho-TBK1/NAK (Ser172) Antibody [G18L12] | NAK/TBK1 (phospho S172),Phospho-TBK1/NAK (Ser172) | Dec 12 2025 |
| F4919 | Myc tag Antibody [A14H15] | Dec 12 2025 | |
| E8323 | Emeramide | Emeramide functions as a thiol-based redox antioxidant and chelates heavy metals. | Dec 10 2025 |
| E0848 | Pinealon | Pinealon is a tripeptide exhibiting neuroprotective effects. This peptide inhibits reactive oxygen species (ROS) buildup and blocks ERK 1/2 activation. It enhances functional activity of key brain tissue cellular components while decreasing spontaneous cell death rates. Studies demonstrate Pinealon's protective effects against prenatal hyperhomocysteinemia in rat offspring. | Dec 10 2025 |
| E6646 | BMS-986260 | BMS-986260 is an orally active immuno-oncology agent that inhibits TGF R1 with an IC50 of 1.6 nM. It shows selectivity for TGF R1 compared to TGF R2 and over 200 other kinases. In MINK and NHLF cell lines, BMS-986260 blocks TGF -induced pSMAD2/3 nuclear translocation with IC50 values of 350 nM and 190 nM, respectively. | Dec 09 2025 |
| E6560 | naperiglipron | Naperiglipron (LY3549492) (Example 2) acts as a glucagon-like peptide 1 receptor (GLP-1R) agonist, exhibiting an EC50 of 1.14 nM at hGLP-1R. In GLP-1R knock-in mouse models, it reduces blood glucose levels. The compound shows PDE10A1 enzyme inhibitory activity (IC50: 7.43 μM) and displays weak hERG inhibition. Naperiglipron has potential applications in type II diabetes mellitus (T2DM) and obesity studies. | Dec 08 2025 |
| E6639 | Auceliciclib (AU3-14,Ulecaciclib ) | Ulecaciclib is an orally active cyclin-dependent kinase (CDK) inhibitor with Ki values of 0.62 μM for CDK2/Cyclin A, 0.2 nM for CDK4/Cyclin D1, 3 nM for CDK6/Cyclin D3, and 0.63 μM for CDK7/Cyclin H. This compound demonstrates blood-brain barrier penetration and favourable pharmacokinetic properties. | Dec 04 2025 |
| P1231 | Mazdutide (IBI362, LY330567) | Mazdutide (IBI-362; LY-3305677) is a synthetic long-acting oxyntomodulin analog that functions as a dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and Glucagon Receptor (GCGR). The compound exhibits binding affinity for human and mouse GCGR (Ki values of 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki values of 28.6 nM and 25.1 nM, respectively). In mouse islets, mazdutide stimulates insulin secretion with an EC50 of 5.2 nM. This agent has been investigated in research related to obesity and type 2 diabetes (T2D). | Dec 04 2025 |
| E6643 | SS-3091 | SS-3091 is a potent inhibitor of pan-KRas that targets the interaction interfaces of KRas, destabilizing critical KRas–protein complexes and thereby blocking its downstream signaling pathways. SS-3091 effectively inhibits KRas-driven signaling in multiple cancer cell lines, including those harboring G12D, G12V, and G13D mutations, leading to reduced ERK and AKT phosphorylation. | Dec 04 2025 |
| E5927 | Mito-LND (Mito-Lonidamine) | Mito-LND (Mito-Lonidamine) is a mitochondria-targeted derivative of lonidamine conjugated with a triphenylphosphonium cation that selectively accumulates in cancer cell mitochondria due to their high membrane potential. It potently inhibits oxidative phosphorylation (OXPHOS) by disrupting respiratory complexes I and II, stimulating ROS production and Prx3 oxidation while suppressing AKT/mTOR/p70S6K signalling. | Dec 04 2025 |
| E6511 | ADT-1004 | ADT-1004 is an orally bioavailable prodrug of ADT-007, that acts as a first-in-class selective inhibitor of pan-RAS with potent antitumor activity in pancreatic ductal adenocarcinoma (PDAC) models. | Dec 04 2025 |
| E6526 | MCB-294 | MCB-294 is a pan-KRAS inhibitor that targets both active (GTP-bound) and inactive (GDP-bound) KRAS states, exhibiting Kd values of about 1 pM and 10 nM, respectively. It shows preferential inhibition of KRAS over NRAS and HRAS. The compound inhibits proliferation of hTERT-HPNE cells harbouring G12D, G12C, G12V, G12S, G13D, and wild-type KRAS variants, with IC50 values around 700 nM. MCB-294 triggers apoptosis in KRAS-mutated tumours and demonstrates activity against KRASG12C inhibitor-resistant cancer cells while modulating the tumour immune microenvironment. This compound serves as a research tool for pancreatic, colorectal, and lung cancer investigations. | Dec 04 2025 |
| E5936 | FT895 | FT895 inhibits HDAC11 with an IC50 of 3 nM. | Dec 04 2025 |
| E6647 | Bireociclib (XZP-3287,CDK4/6-IN-2) | CDK4/6-IN-2 is a CDK4 and CDK6 inhibitor obtained from patent US20180000819A1 (Compound 1). It exhibits IC50 values of 2.7 nM for CDK4 and 16 nM for CDK6. | Dec 04 2025 |
| E6638 | VS-7375 (GFH375) | VS-7375 (GFH375) is an oral small-molecule inhibitor that selectively targets KRAS G12D in both its active (GTP-bound) and inactive (GDP-bound) forms. This dual-state inhibition results in stronger tumour suppression compared to single-state inhibitors. It exhibits potent anti-proliferative and anti-tumour effects in KRAS G12D-mutant models, including an intracranial GP2D tumour model. | Dec 04 2025 |
| E6517 | PKN1 | PKN1/2-IN-1 is a cell-permeable compound that inhibits PKN1 and PKN2, with IC50 values of 16 nM and 210 nM, and Ki values of 8 nM and 108 nM, respectively. In NanoBRET assays, it shows intracellular PKN2 binding with an IC50 of 2.1 μM. This compound is applicable for investigating tumour cell migration and related physiological processes. | Dec 02 2025 |
| E6521 | HRS‑5346 | Lp(a)-IN-5 (Compound A) is an orally administered lipoprotein(a) (Lp(a)) inhibitor. This compound demonstrates inhibition of Apo(a) and ApoB protein assembly with an IC50 of 0.41 nM. It may be useful for studying diseases associated with increased plasma Lp(a) levels, including cardiovascular disorders. | Dec 02 2025 |
| E6578 | AS1708727 | AS1708727 is an orally bioavailable Foxo1 inhibitor that exhibits EC50 values of 0.33 μM against G6Pase and 0.59 μM against PEPCK. | Dec 02 2025 |
| E6498 | Atebimetinib (IMM-1-104) | Atebimetinib inhibits MEK tyrosine kinase and demonstrates antineoplastic effects. | Dec 02 2025 |
| E6636 | DY268 | DY268 is a farnesoid X receptor (FXR) antagonist with an IC50 of 7.5 nM. In cellular assays, it inhibits FXR transactivation with an IC50 of 468 nM. This compound has applications in drug-induced liver injury (DILI) research. | Nov 25 2025 |
| E6634 | Thiethylperazine | Thiethylperazine is a phenothiazine derivative that acts as an oral Dopamine D2-Receptor and histamine H1-receptor antagonist. This compound functions as an ABCC1 activator and has been shown to decrease amyloid-β (Aβ) accumulation in mice. It exhibits anti-emetic, antipsychotic, and antimicrobial properties. | Nov 25 2025 |
| E6565 | Ofirnoflastum | Ofirnoflast (Ofirnoflastum) inhibits serine/threonine-protein kinase Nek7 and exhibits anti-inflammatory activity. | Nov 24 2025 |
| E6572 | AD1058 | AD1058 is an orally bioavailable ATR inhibitor with blood-brain barrier permeability (IC50 = 1.6 nM). It demonstrates antitumor effects through inhibition of tumour cell proliferation, induction of cell cycle arrest, and promotion of apoptosis. This compound is applicable for studies involving advanced malignancies and brain metastases. | Nov 24 2025 |
| E6588 | LY3509754 | LY3509754 (IL-17A inhibitor 1) inhibits IL-17A, showing IC50 values of <9.45 nM in alphalisa assay and 9.3 nM in HT-29 cells. | Nov 24 2025 |
| E4617 | Gly-β-MCA | Gly-β-MCA is a bile acid derivative that functions as a stable, orally active, and intestine-specific farnesoid X receptor (FXR) antagonist with potential therapeutic applications in metabolic diseases. | Nov 21 2025 |
| E1219 | CSN5i-3 | CSN5i-3 is a selective, orally bioavailable CSN5/Jab1 inhibitor that demonstrates potent activity in suppressing CSN-mediated Cul1 deneddylation, exhibiting an IC50 of 5.8 nM. | Nov 21 2025 |
| E8318 | T6167923 | T6167923 is a selective MyD88-dependent signalling pathway inhibitor that directly interacts with the Toll/IL-1 receptor (TIR) domain of MyD88, preventing its homodimerization. This compound demonstrates inhibitory effects on NF-κB-mediated Staphylococcus enterotoxin AP (SEAP) activity and exhibits anti-inflammatory properties, with IC50 values of 2.7 μM (IFN-γ), 2.9 μM (IL-1β), 2.66 μM (IL-6), and 2.66 μM (TNF-α). | Nov 21 2025 |
| E1892 | FM4-64 | FM4-64 is a very lipophilic, water-soluble styryl dye that specifically binds to cell membranes and inner membrane organelles to produce fluorescence upon insertion into lipid bilayers. It is widely used as a marker for endocytic and exocytic membrane structures, tracking vesicle trafficking in live cells with minimal aqueous background fluorescence. | Nov 21 2025 |
| E1162 | GLPG0974 | GLPG0974 is a potent and selective antagonist of the human free fatty acid receptor 2 (FFA2/GPR43) with an IC50 of 9 nM and also inhibits SCFA‐induced neutrophil activation and migration. | Nov 21 2025 |
| E1888 | NIM811 ((Melle-4)cyclosporin) | NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is an orally administered dual inhibitor targeting mitochondrial permeability transition and cyclophilin, demonstrating strong in vitro antiviral activity against hepatitis C virus (HCV). | Nov 21 2025 |
| E4757 | Setidegrasib (ASP3082) | ASP3082 (Setidegrasib; KRAS G12D inhibitor 17) is a PROTAC degrader targeting KRAS(G12D) with a DC50 of 38 nM. It effectively inhibits growth in various KRAS(G12D)-mutated cancer cell lines, including pancreatic (PK-59, HPAC) and colorectal (GP2d, GP5d) with IC50 values ranging from 3.6 to 29 nM. | Nov 20 2025 |
| E5832 | BBI-2779 | BBI-2779 is a potent, selective, and orally active inhibitor of CHK1 with an IC50 of 0.3 nM. It preferentially kills cancer cells containing extrachromosomal DNA (ecDNA) by inducing replication stress and cell death. In gastric cancer models with FGFR2 gene amplification on ecDNA, BBI-2779 suppresses tumour growth and prevents drug resistance. | Nov 20 2025 |
| E5858 | Chiglitazar (Carfloglitazar) | Chiglitazar (Carfloglitazar) is a potent dual agonist of PPARα and PPARγ with EC50 values of 1.2 μM and 0.08 μM, respectively, and also activates PPARδ with an EC50 of 1.7 μM. It effectively improves insulin resistance and corrects dyslipidaemia in monosodium L-glutamate (MSG)-induced obese rats. | Nov 20 2025 |
| E5859 | Acivicin hydrochloride | Acivicin hydrochloride (AT-125 hydrochloride) is the hydrochloride salt of Acivicin, a natural antibiotic produced by Streptomyces sviceus. It is a potent inhibitor of γ-glutamyl transpeptidase (GGT), an enzyme that initiates glutathione catabolism to cysteine. Acivicin also exhibits anti-cancer and anti-parasitic properties. | Nov 20 2025 |
| E5860 | 20-HETE | 20-HETE (20-Hydroxyeicosatetraenoic acid) is a cytochrome CYP450-derived metabolite of arachidonic acid that plays a dual role in blood pressure regulation. It lowers blood pressure by inhibiting sodium reabsorption and promoting natriuresis in the kidneys, but also raises blood pressure by sensitising vascular smooth muscle to constrictors, increasing myogenic tone, and inducing endothelial dysfunction. Additionally, 20-HETE stimulates endothelial angiotensin-converting enzyme (ACE), activating a prohypertensive renin-angiotensin-aldosterone system (RAAS) feedback loop that contributes to hypertension and vascular remodelling. | Nov 20 2025 |
| E1983 | BAY-850 | BAY-850 is a potent and isoform-selective inhibitor of the ATPase family AAA domain-containing protein 2 (ATAD2) bromodomain, with an IC50 of 166 nM in TR-FRET assays. It induces ATAD2 bromodomain dimerization and effectively blocks its interaction with acetylated histones in vitro. | Nov 20 2025 |
| E2989 | AZD5904 | AZD5904 is a selective and irreversible human Myeloperoxidase (MPO) inhibitor. AZD5904 reduces 3-chlorotyrosine-modified MYBPC3 levels, restores MYBPC3 phosphorylation, and alleviates the calcium signalling and relaxation defects. | Nov 20 2025 |
| E5915 | Moracin O | Moracin O is a 2-arylbenzofuran isolated from the Morus alba Linn. Moracin O demonstrates potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1) with an IC50 value of 6.76 nM in a cell-based HRE assay. Moracin O attenuates reactive oxygen species (ROS) generation triggered by oxygen-glucose deprivation (OGD). Moracin O also exhibits neuroprotective and anti-inflammatory effects. | Nov 20 2025 |
| E5946 | C12FDG | C12FDG (5-Dodecanoylaminofluorescein di-β-D-galactopyranoside) is a lipophilic green fluorescent probe used to detect β-galactosidase activity. C12FDG demonstrates greater sensitivity for measuring β-galactosidase activity in animal cells than fluorescein di(β-D-galactopyranoside). | Nov 20 2025 |
| E4747 | BMS-986408 | BMS-986408 is a first-in-class dual inhibitor of DGKα and DGKζ, exhibiting IC₅₀ values of 0.0003 μM and 0.002 μM for DGKα and DGKζ lipid kinase activity, respectively. It potentiates T cell–receptor signaling and T-cell activation, enhancing the effectiveness of both PD-1 and CAR T-cell therapy in preclinical models. | Nov 20 2025 |
| E6600 | 3FAx-Neu5Ac | 3Fax-Neu5Ac is a fluorinated sialic acid analogue that inhibits sialyltransferase activity, reduces cellular sialylation, and leads to decreased MHC expression and suppression of myoblast fusion, thereby demonstrating potential in regulating skeletal muscle cell differentiation. | Nov 20 2025 |
| E6603 | USP5-IN-1 | USP5-IN-1 (compound 64) is a selective competitive inhibitor of USP5 zinc finger ubiquitin binding domain (ZnF-UBD) with a Kd of 2.8 μM. It competitively blocks ubiquitin binding to the ZnF-UBD domain, suppressing USP5 catalytic activity and ubiquitin chain hydrolysis, with potential applications as a chemical probe and therapeutic agent in USP5-related cancers. | Nov 20 2025 |
| E6614 | FABPs ligand 6 (MF6) | FABPs ligand 6 (MF6) is a potent dual inhibitor of FABP5 and FABP7 with KD values of 874 nM and 20 nM, respectively. It rescues mitochondrial function and mitigates FABP5/FABP7-mediated injury, demonstrating potential therapeutic effects in multiple sclerosis (MS). | Nov 20 2025 |
| E6610 | GPX4-IN-5 | GPX4-IN-5 covalently inhibits GPX4 with an IC50 of 0.12 μM. This compound induces ferroptosis and exhibits anti-tumor activity. It has potential applications in triple-negative breast cancer (TNBC) research. | Nov 20 2025 |
| E2949 | Talarozole (R115866) | Talarozole (R115866) is a potent, orally active inhibitor of cytochrome P450 (CYP26)-mediated metabolism of All-trans-retinoic acid (RA). It inhibits the conversion of RA by CYP26, with an IC50 of 0.004 µM, and enhances endogenous RA levels and All-trans-retinoic acid receptor (RAR) activation, showing potential as a targeted agent for dermatological therapy. | Nov 20 2025 |
| E1154 | DS18561882 | DS18561882 is a potent, tricyclic coumarin-based inhibitor of MTHFD2 with an IC50 of 0.0063 μM, exhibiting significant selectivity over the cytosolic isozyme MTHFD1. It also effectively inhibits tumour growth in mouse xenograft models in vivo. | Nov 20 2025 |
| P1253 | Allo-aca (ARV-1803) | Allo-aca (ARV-1803) is a synthetic peptide that functions as a specific antagonist of the leptin receptor, effectively blocking leptin signalling in both in vitro and in vivo. It also demonstrates potential therapeutic applications in the treatment of ophthalmic diseases. | Nov 20 2025 |
| P1267 | CIRC-014 | CIRC-014 is an orally bioavailable cyclin A/B RxL macrocyclic inhibitor. CIRC-014 displays robust anti-tumor activity in chemo-resistant small cell lung cancer (SCLC) PDX models and induces SAC activation and apoptosis in vivo. | Nov 20 2025 |
| E6608 | HSK31858 | HSK31858 is a reversible inhibitor of DPP-1. It promotes the amelioration of neutrophilic inflammation, demonstrating efficacy and safety in reducing exacerbation frequency in adults with bronchiectasis. | Nov 20 2025 |
| E1963 | ARV-393 | ARV-393 is a highly potent, orally bioavailable BCL6 PROTAC degrader. ARV-393 promotes rapid BCL6 degradation through the cells ubiquitin-proteasome pathway. ARV-393 demonstrates DC50 and GI50 values <1 nM in numerous DLBCL and BL cell lines. | Nov 19 2025 |
| F5072 | Cox1 Antibody [N11K4] | Nov 12 2025 | |
| F1062 | E2F-1 Antibody [N6L18] | E2F 1,E2F1,E2F-1 | Nov 12 2025 |
| F0405 | Phospho-c-Fos (Ser32) Antibody [H14J15] | Nov 12 2025 | |
| F2850 | JAK2 Antibody [J11G12] | Nov 12 2025 | |
| F4416 | PGC1α/β Antibody [H5N22] | Nov 12 2025 | |
| F4661 | Keratin 20 Antibody [L17C14] | Nov 12 2025 | |
| F4337 | Claudin 7 Antibody [M7D16] | Nov 12 2025 | |
| F3666 | ERAB Antibody [M20E24] | Nov 12 2025 | |
| F4995 | METTL3 Antibody [F21G6] | Nov 12 2025 | |
| F4131 | c-Fos Antibody [B8E19] | Nov 12 2025 | |
| F4147 | HER2/ErbB2 Antibody [G18G3] | Nov 12 2025 | |
| F2178 | CXCR4 Antibody [G11H20] | CXCR4,CXCR-4 | Nov 12 2025 |
| E6559 | GS-1427 | GS-1427 (Emvistegrast) is an oral, small-molecule quinolone derivative that functions as a potent and selective antagonist of α4β7 integrin, with the potential treatment of inflammatory bowel disease. | Nov 12 2025 |
| F3553 | Phospho-SMAD2 (Ser245/250/255) Antibody [H4M3] | Nov 10 2025 | |
| F3893 | Phospho-PERK (Thr982) Antibody [A3P5] | Nov 10 2025 | |
| F4139 | Phospho-VEGF Receptor 2 (Tyr1175) Antibody [M10N15] | Nov 10 2025 | |
| F4141 | NRF2 Antibody [J1K11] | Nov 10 2025 | |
| F4089 | Phospho-EGF Receptor (Tyr1173) Antibody [E8J4] | Nov 10 2025 | |
| F4198 | Glut1 Antibody [C8B12] | Nov 10 2025 | |
| F4188 | PGC-1α Antibody [J17F10] | Nov 10 2025 | |
| F0348 | Phospho-Smad1/5 (Ser463/465) Antibody [H6D11] | Nov 10 2025 | |
| E6539 | SHOC2–RAS PPI-IN-1 | SHOC2-RAS PPI-IN-1 (compound 6) is a non-covalent competitive inhibitor that disrupts the SHOC2-RAS protein-protein interaction. It exhibits an IC50 of 0.048 μM and a KD of 0.065 μM against NRASQ61R. The compound inhibits the SMP phosphatase complex, resulting in elevated CRAFS259 phosphorylation and subsequent blockade of the MAPK signalling pathway (evidenced by reduced pMEK and pERK levels). This inhibition induces tumour cell cycle arrest and Apoptosis. SHOC2-RAS PPI-IN-1 serves as a research tool for investigating NRASQ61R-mutant malignancies including melanoma and colorectal cancer. | Nov 10 2025 |
| F1277 | CISH Antibody [J15C14] | Nov 10 2025 | |
| F0256 | Phospho-VEGF Receptor 2 (Tyr1175) Antibody [M9C2] | Phospho-VEGF Receptor 2 (Tyr1175), VEGF Receptor 2 (phospho Y1175) | Nov 10 2025 |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.